Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-01-22 @ 6:53 PM
Study NCT ID:
NCT06796803
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-02-10
First Post:
2025-01-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
MA-HCC-II/III-026
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |